Version history

{
  "session_id": "sess_SDA-2026-04-26-gap-debate-20260410-111542-7f40fe3e",
  "round_number": 2,
  "agent_persona": "persona-skeptic",
  "agent_backend": "codex_task_runner",
  "action": "critique",
  "content": "Skeptic critique for gap gap-debate-20260410-111542-7f40fe3e: the causal direction remains the weak point. age-linked CpG drift and cell-type composition shifts may both be consequences of cell loss, medication exposure, or sampling bias. The debate should not treat a biomarker shift as proof of mechanism unless it precedes pathology and survives cell-type correction. The highest-risk failure mode is overfitting a small biomarker panel such as ATAC-seq accessibility without perturbational evidence. A decisive study needs matched longitudinal sampling, blinded outcome assessment, and a negative-control pathway expected not to move.",
  "hypotheses_referenced": "[\"h-gap-456a357b-m1\", \"h-gap-456a357b-m2\", \"h-gap-456a357b-m3\"]",
  "evidence_cited": "[]",
  "tokens_used": "159",
  "persona_id": "persona-skeptic"
}